Arvaya Healthcare Corrects FY26 EPS, Details Healthcare Transformation

Arvaya Healthcare Limited, formerly known as Bijoy Hans Limited, has issued a corrigendum to its audited financial results for the fiscal year ended March 31, 2026. The company corrected an error in the reporting of its Earnings Per Share (EPS).

Reader Takeaway: EPS correction confirms profit; healthcare transition is key.

What just happened

The company announced a corrigendum to its audited financial results, specifically rectifying an error in the Earnings Per Share (EPS) calculation. For FY 2025-26, the standalone basic EPS was corrected to ₹0.45 from a previously reported figure, and the consolidated basic EPS to ₹0.69.

The company also reported its financial snapshot for FY 2025-26. Standalone revenue from operations stood at ₹0.28 crore, with a profit of ₹0.14 crore. Consolidated revenue was ₹9.11 crore, and profit was ₹0.90 crore. These consolidated figures include just 27 days of operations from newly acquired subsidiaries.

Why this matters

This filing is significant as it marks the formal transition of the company into the healthcare sector. The acquisition of three healthcare entities – Health Secure Hospitals Private Limited, Arvaya Health and Wellness Private Limited, and Tec-Pool Solutions Private Limited – on March 4, 2026, signals a major business model shift. The consolidated financials, though only reflecting a partial period for the new entities, give an initial glimpse into the company's new operational scale. The correction in EPS, while important for accuracy, does not alter the core profit numbers previously disclosed.

The backstory

Arvaya Healthcare Limited operated under the name Bijoy Hans Limited before its strategic pivot. The company has recently completed acquisitions to establish its presence in the healthcare industry. In preparation for its new business direction, Arvaya Healthcare also increased its authorized share capital from ₹60 crore to ₹200 crore.

What changes now

Investors will now see the company's performance through the lens of its healthcare operations. The consolidated results, while still nascent for the acquired businesses, will become the primary indicator of future performance. The company is also managing provisional goodwill of ₹20.32 crore recognized from these acquisitions, which will be subject to impairment testing.

Risks to watch

A notable risk is the pending litigation concerning consultant claims, representing a potential contingent liability of ₹3.72 crore. While a commercial court ruled in the company's favor, an appeal is ongoing in the High Court. Additionally, the goodwill recognized from acquisitions requires ongoing scrutiny through impairment testing.

Peer comparison

As Arvaya Healthcare diversifies into healthcare, its performance will be benchmarked against other healthcare service providers in India. Key metrics to watch will include revenue growth, profitability margins, and patient acquisition costs within the healthcare services sector.

Context metrics (time-bound)

Consolidated revenue from operations for FY 2025-26: ₹9.11 crore (₹911.33 lakh), representing only 27 days of operations from new subsidiaries.
Consolidated profit for the period: ₹0.90 crore (₹90.38 lakh).
Standalone revenue from operations: ₹0.28 crore (₹27.89 lakh).
Standalone profit for the period: ₹0.14 crore (₹13.61 lakh).
Basic EPS (Standalone, corrected): ₹0.45.
Basic EPS (Consolidated, corrected): ₹0.69.
Acquisition dates: March 4, 2026.
Provisional goodwill recognized: ₹20.32 crore.
Potential contingent liability: ₹3.72 crore.

What to track next

Investors should closely monitor the integration of the newly acquired healthcare entities and their contribution to revenue and profits in the coming quarters. The outcome of the ongoing litigation and the annual impairment testing for goodwill will also be crucial factors to track.